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ABSTRACT           
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive 
fibrosis of skin and multiple internal organs and severe functional and structural microvascular 
alterations. SSc is considered to be the prototypic systemic fibrotic disorder. Despite currently 
available therapeutic approaches SSc has a high mortality rate owing to the development of 
SSc-associated interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH), 
complications that have emerged as the most frequent causes of disability and mortality in SSc. 
The pathogenesis of the fibrotic process in SSc is complex and despite extensive investigation 
the exact mechanisms have remained elusive. Myofibroblasts are the cells ultimately 
responsible for tissue fibrosis and fibroproliferative vasculopathy in SSc. Tissue myofibroblasts 
in SSc originate from several sources including expansion of quiescent tissue fibroblasts and 
tissue accumulation of CD34+ fibrocytes. Besides these sources, myofibroblasts in SSc may 
result from the phenotypic conversion of endothelial cells into activated myofibroblasts, a 
process known as endothelial to mesenchymal transition (EndoMT). Recently, it has been 
postulated that EndoMT may play a role in the development of SSc-associated ILD and PAH. 
However, although several studies have described the occurrence of EndoMT in experimentally 
induced cardiac, renal, and pulmonary fibrosis and in several human disorders, the contribution 
of EndoMT to SSc-associated ILD and PAH has not been generally accepted. Here, the 
experimental evidence supporting the concept that EndoMT plays a role in the pathogenesis of 
SSc-associated ILD and PAH will be reviewed.  
 
Keywords: Systemic Sclerosis, Fibrosis, Interstitial Lung Disease, Pulmonary Fibrosis, 
Pulmonary Arterial Hypertension, EndoMT, Endothelial cell, Myofibroblast. 
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INTRODUCTION 
            Systemic Sclerosis (SSc) is a systemic autoimmune disease of unknown etiology 
characterized by progressive fibrosis of skin and multiple internal organs, and severe functional 
and structural fibroproliferative alterations in the microvasculature [1-3]. Although numerous 
studies have examined the pathogenesis of SSc the exact mechanisms involved are not well 
understood and have remained elusive [4-7]. However, it has been recognized that the most 
serious clinical manifestations of the disease and its high mortality are the result of SSc-
associated-interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH). SSc-
associated ILD results from exaggerated and often progressive accumulation of fibrous 
collagens and other extracellular matrix molecules in the lung parenchyma, whereas, SSc-
associated PAH is caused by functional alterations and structural fibroproliferative vasculopathy 
affecting the small and medium sized pulmonary arterioles [8-12].  
The cells ultimately responsible for the severe fibrotic process affecting the lung 
parenchyma and for the fibroproliferative alterations in the small and middle size pulmonary 
arterioles in SSc are the activated myofibroblasts [13-18]. Myofibroblasts are a unique 
population of mesenchymal cells displaying a marked profibrotic cellular phenotype 
characterized by the increased production of fibrillar type l and type lll collagens, initiation of 
expression of α-smooth muscle actin (α-SMA), and reduction in the expression of genes 
encoding ECM-degradative enzymes [19-23]. Myofibroblasts also acquire a motile behavior and 
pronounced contractile properties, features that allow them to migrate to unaffected tissues and 
to induce a progressive increase in tissue stiffness, a recently recognized potent profibrotic 
stimulus [24,25]. Given the crucial role of myofibroblasts in the pathogenesis of organ-specific 
and systemic fibrotic disorders there has been wide-ranging interest in the precise identification 
of their origin [26-28]. Extensive research studies have shown that myofibroblasts originate from 
diverse sources including expansion and activation of quiescent resident tissue fibroblasts [29], 
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migration and tissue accumulation of bone marrow-derived circulating CD34+ fibrocytes [30-32], 
or from epithelial cells or perivascular cells (pericytes) that have undergone a phenotypic 
transition into mesenchymal cells [33-35]. More recent studies, however, have demonstrated 
that another source of activated myofibroblasts are endothelial cells (EC) that have acquired a 
mesenchymal phenotype through a process known as endothelial to mesenchymal transition 
(EndoMT). During EndoMT EC lose their specific EC markers such as CD31/PECAM-1, von 
Willebrand Factor (vWF), and VE-cadherin, and initiate the expression of mesenchymal cell 
products including α–SMA, vimentin, and type I collagen [36,37]. Despite the demonstration of 
the occurrence of EndoMT in numerous animal models of experimentally-induced cardiac, 
pulmonary, and renal fibrosis [37-43], and several studies suggesting a role for EndoMT in the 
pathogenesis of various human disorders [37,44-50], the possibility that EndoMT participates in 
the development or progression of the fibrotic process or the fibroproliferative vasculopathy in 
SSc has not been generally accepted. 
Here, we will review the available experimental evidence that supports a role for 
EndoMT in the pathogenesis of SSc-associated ILD and PAH. First, we will briefly review the 
evidence that certain pathways that have been shown to participate in SSc-pathogenesis also 
play a role in EndoMT as depicted in Figure 1. Secondly, we will discuss the occurrence of 
EndoMT in experimental models of pulmonary fibrosis and pulmonary vascular disease. Finally, 
we will review the available evidence that supports a role of EndoMT in various human 
disorders and will discuss studies supporting the notion that the phenotypic change from EC to 
activated myofibroblasts participates in the development of SSc-associated ILD and PAH. 
1. ROLE OF PATHWAYS INVOLVED IN SSC PATHOGENESIS IN THE MOLECULAR 
MECHANISMS OF ENDOMT.  
1.1 The TGF-β pathway. Given the crucial role that TGF-β plays in the development of 
tissue fibrosis and in the pathogenesis of numerous fibrotic diseases including SSc [51-54] 
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several studies have investigated the role of this extended family of profibrotic growth factors in 
the generation of myofibroblasts through EndoMT [55-58]. The detailed molecular events and 
the intracellular cascades activated by TGF-β that result in the phenotypic change of EC into 
mesenchymal cells have not been entirely elucidated. However, several studies have shown 
that both Smad-dependent and Smad-independent pathways and numerous transcriptional 
regulators such as Snail1, Snail2 (or Slug), Twist, and some members of Zeb family of proteins 
are involved [55-59]. We recently examined the intracellular transduction pathways mediating 
TGF-β-induced EndoMT in cultured murine lung EC.  We found that TGF-β induction of 
EndoMT was mediated by the c-Abl kinase and by protein kinase c-δ and was associated with a 
strong upregulation in the expression of Snail-1 [60].  
1.2. Caveolin-1 (CAV1). CAV1, the main protein component of caveolae plays an 
important role in the internalization, trafficking and degradation of TGF-β receptors and, 
therefore, is involved in the regulation of TGF-β signaling and TGF-β-mediated fibrotic 
responses [61,62]. Extensive studies in Cav1 knock out mice (Cav1-/-) showed that these mice 
exhibited a remarkable phenotype characterized by extensive fibrotic tissue accumulation in 
skin and lungs [63].  Following these observations several groups examined whether CAV1 may 
play a role in human fibrotic disorders and described that CAV1 protein and gene expression 
were markedly decreased in affected tissues from patients with SSc and SSc-associated ILD as 
well as in lung tissues from patients with idiopathic pulmonary fibrosis [63-65]. Restoration of 
CAV1 functional domains by supplementation with a caveolin scaffolding domain peptide or by 
adenoviral-mediated expression of CAV1 corrected the profibrotic phenotype of SSc and IPF 
cells in vitro [63-65] and in vivo in animal models of pulmonary fibrosis and PAH, including the 
monocrotaline-induced model of PAH and the bleomycin-induced pulmonary fibrosis in mice 
[64-66]. These studies, however, did not examine whether CAV1 was involved in EndoMT. To 
address this point, we examined the role of CAV1 in EndoMT employing immunopurified EC 
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isolated from lungs of Cav1-/-mice [67]. The results demonstrated the spontaneous occurrence 
of EndoMT in   Cav1-/- pulmonary EC as evidenced by the constitutive expression of -SMA, 
the high levels of production of type I collagen, and the high expression of the transcriptional 
repressors Snai1  and Snai2, molecules previously shown to be upregulated in TGF-β1-induced 
EndoMT. These observations demonstrated that EndoMT occurred spontaneously in Cav1-/- 
mice in vivo and suggested that CAV1 deficiency, a molecular alteration that is a characteristic 
feature of SSc cells, may participate in the development of the progressive tissue fibrosis and 
proliferative vasculopathy in the disease through the establishment of EndoMT.  
1.3. The role of endothelin-1 (ET-1) in EndoMT. Besides its crucial role in the 
development of primary and secondary PAH, a growing body of evidence has implicated ET-1 
as a participant in organ fibrosis and numerous studies have considered it as an important 
trigger of the fibrotic process in SSc [68-70]. Although ET-1 is a major vasoactive peptide with 
multiple effects on EC it is not known whether it is capable of inducing EndoMT. Recent studies 
have examined whether ET-1 may also participate in the development of tissue fibrosis by 
inducing EndoMT. In one study, Widyantoro, et al. [71] showed that EC-derived ET-1 promotes 
cardiac fibrosis and heart failure in diabetic hearts through stimulation of EndoMT. In recent 
studies from our group employing murine lung EC it was found that although ET-1 was not 
capable of inducing EndoMT by itself it potentiated TGF-β-induced EndoMT. In subsequent 
studies we showed that cultured CD31+ human EC cells also were induced to undergo EndoMT 
in vitro when treated with ET-1 in the presence of TGF-β (Wermuth and Jimenez, unpublished 
observations). In these studies we also demonstrated that ET-1 exerted potent synergistic 
stimulation on TGF-β effects on EndoMT.  A similar study employing immunopurified CD31 
dermal EC from SSc patients and from normal individuals showed that TGF-β and ET-1 induced 
EndoMT in normal and SSc-EC and that these effects involved the Smad pathway and were 
blocked by the ET-1 receptor antagonist, macitentan [72]. The results of the studies with human 
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EC demonstrate that ET-1 is capable of generating either by itself or in combination with TGF-β 
activated tissue myofibroblasts through EndoMT. These studies also provide a novel 
mechanism for ET-1 participation in the development of tissue fibrotic reactions. 
1.4. Role of Notch and Hedgehog signaling pathways. The morphogens Notch and 
Hedgehog play crucial roles during embryonic development [73-76]. Although in the adult these 
pathways are tightly regulated, under some circumstances their aberrant activation may occur 
leading to serious pathological consequences, including fibrotic diseases. Indeed, there are 
numerous recent publications implicating alterations in Notch pathways in the pathogenesis of 
SSc and other fibrotic diseases [77-79].  
Although not extensively studied, it has recently become apparent that Notch pathways 
may also participate in the regulation of EndoMT. The role of Notch signaling in EndoMT was 
first described by Noseda, et al. [80] and it was suggested that the Notch pathway may be 
crucial for heart valve and cardiac cushion development and/or vascular smooth muscle 
differentiation [81,82]. In human microvascular EC, Notch and TGF-β synergistically stimulate 
Snail expression and upregulate a subset of genes by recruiting Smad3 to Smad binding sites 
[81-83]. However, while there is limited, although significant information, concerning the 
interaction of Notch and TGF-β signaling in EndoMT, the potential role of Notch in SSc-
associated ILD and fibroproliferative vasculopathy has not been studied.  
Another important pathway that has been shown to participate in the pathogenesis of 
various fibrotic disorders is the Sonic Hedgehog (SHh) pathway [84-88]. Recently, an extensive 
study [89] showed increased SHh expression in SSc affected tissues and demonstrated that 
TGF-β increased its expression. Characterization of the cells displaying increased SHh 
expression employing immunofluorescence for SHh epitopes showed intense EC staining in 
affected SSc skin. Furthermore, SHh was capable of strong stimulation of fibroblast to 
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myofibroblast transition with a potency similar to that of TGF-β [89].  However, the possibility 
that SHh may be involved in EndoMT has not been examined. 
1.5. Wnt pathway activation. Wnts comprise a multigene family of secreted 
glycoproteins that play crucial roles during embryogenesis signaling through canonical and non-
canonical pathways [90,91]. Following binding of Wnt ligands to their specific cell surface 
receptor and co-receptors the activation of glycogen synthetase kinase (GSK)-3ß is inhibited 
resulting in the accumulation of unphosphorylated β-catenin in the cytoplasm, followed by its 
translocation into nucleus, and the activation of target genes. Secreted Frizzled-related proteins 
(SFRP), Wnt inhibitory factors and other Wnt inhibitors such as Dkk-1 have been shown to 
negatively modulate Wnt responses [90,91]. Recent studies showed that the Wnt/β-catenin 
pathway is involved in the activation of numerous profibrotic steps in SSc pathogenesis [92-95]. 
Indeed, increased Wnt activation has been found in skin biopsies from SSc patients and it was 
further shown that Wnt3a induced myofibroblast differentiation via Smad-dependent autocrine 
TGF-β signaling promoting pathologic fibrogenesis [93]. A crucial role of β-catenin as a 
mediation of the profibrotic effects of the Wnt pathway was also demonstrated [94]. It was also 
shown that the Wnt pathway antagonists Dkk-1 and SFRP1 were epigenetically downregulated 
in SSc cells [95]. Similar findings were also obtained in SSc-associated lung fibrosis with the 
nuclear accumulation of β-catenin in activated fibroblasts present in fibroblastic foci in the lungs 
of patients with SSc-associated ILD [96]. Despite these observations very few studies have 
examined the role of Wnt pathway activation on the generation of activated myofibroblasts 
through EndoMT. One recent study demonstrated that induction of canonical Wnt signaling 
resulted in EndoMT pathway activation in cultured EC and in myocardial EC following 
experimentally-induced myocardial infarction [97]. In contrast, two studies showed that the Wnt 
inhibitor Dkk-1 enhanced EndoMT in aortic EC [98] and in human renal glomerular EC cultured 
in a high glucose medium [99] results that indicate that further study is needed to conclusively 
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determine the precise role of Wnt and of its inhibition on EndoMT-induced myofibroblast 
generation.  
 1.6. Involvement of hypoxia in EndoMT.  The transcription factor HIF-1 is the key 
regulatory molecule responsible for the induction of a vast array of cellular and molecular 
responses to hypoxia and has been implicated in various pathologic conditions [100-102].  
Hypoxia-induced dysregulation of HIF-1  expression and activity has been implicated in the 
pathogenesis of various fibrotic disorders including kidney and cardiac fibrosis [103,104]. The 
mechanisms involved in  HIF-1-induced fibrosis are very complex and include activation of a 
vast array of profibrotic genes as shown in global gene expression changes in hypoxic hepatic 
stellate cells [105], stimulation of expression of growth factors such as TGF-β and VEGF, and 
induction of epithelial to mesenchymal transition [106-108]. However, the possibility that hypoxia 
and HIF-1 may mediate some physiologic or pathologic responses through induction of 
EndoMT has just begun to be explored. Indeed, two very recent studies showed that one 
important downstream effect of HIF1- is the induction of EndoMT in human coronary EC and 
that this effect may ultimately lead to development of cardiac fibrosis [109] and that HIF-1 
mediated EndoMT during the development of radiation-induced pulmonary fibrosis [110]. 
2. DEMONSTRATION OF ENDOMT IN ANIMAL MODELS OF PULMONARY 
FIBROSIS.  
Although in the past EndoMT was believed to be a rare phenomenon confined to certain 
stages of human embryonic development [36] numerous studies have described its occurrence 
in various experimental models of fibrosis including cardiac, renal, and pulmonary fibrosis [37-
43]. One of the first studies to evaluate whether EC could represent a source of myofibroblasts 
involved in the development of pulmonary fibrosis examined bleomycin-induced lung fibrosis in 
double-transgenic mice with stable LacZ expression in EC [111]. In this setting any cells 
originated from the EC lineage will be LacZ labeled. Morphological evaluation of lungs from the 
 10 
transgenic mice following endotracheal injection of bleomycin showed that the areas of fibrotic 
involvement contained large numbers of LacZ-positive fibroblasts indicative of their endothelial 
origin. To directly demonstrate the presence of EC–derived fibroblasts, lung fibroblasts from 
either saline-injected control mice or from bleomycin treated mice were isolated and cultured. 
LacZ detection revealed that approximately 16% of lung fibroblasts in the cultures from 
bleomycin-treated mice were derived from EC. Immunocytochemical staining for type I collagen 
and α-SMA showed that some cells from the bleomycin-treated mice expressed LacZ, type I 
collagen, and α-SMA, demonstrating their EC origin. These findings conclusively showed that 
lung EC could give rise to a substantial number of myofibroblasts through EndoMT in the 
bleomycin-induced lung fibrosis model. Furthermore, the study demonstrated that the 
phenotypic change was a permanently acquired trait. Another study examined the occurrence of 
EndoMT in experimentally induced PAH. In this study PAH was induced in mice following 
exposure to hypoxia and treatment with the antiangiogenic compound SU5416, a potent VEGF 
receptor inhibitor [112]. The results showed that approximately 6% of pulmonary arterioles 
displayed colocalization of vWF and -SMA indicative of the occurrence of EndoMT in vivo in 
this animal model [112]. 
Despite the extensive experimental evidence supporting a role of EndoMT in the 
pathogenesis of tissue fibrosis there have been some reports raising controversy as to whether 
EndoMT was indeed a source of activated myofibroblasts contributing to the development of 
fibrotic reactions in vivo [113,114]. However, a recent study using detailed endothelial lineage 
tracing in transgenic mice with experimentally-induced renal fibrosis showed that from 10 to 
20% of fibroblasts in the fibrotic kidneys arise from endothelial cells via EndoMT [42] in vivo, 
and another study in experimentally induced cardiac fibrosis employing rigorous genetic cell 
lineage tracing also showed that a population of cardiac interstitial fibroblasts were of EC origin 
[115]. 
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3. DEMONSTRATION OF ENDOMT IN NON-PULMONARY HUMAN FIBROTIC 
DISEASES. 
Given the intense interest raised by the study of EndoMT in various animal models of 
tissue fibrosis numerous studies have examined the occurrence of EndoMT in human 
pathologic conditions [37,42]. Results from the rapidly growing literature about the possible 
contribution of EndoMT to human disorders has provided strong support to the concept that 
EndoMT may also play a role in the pathogenesis of SSc-associated ILD and PAH. Following 
the pioneering description of Zeisberg et al. of the important role of EndoMT in the development 
of cardiac fibrosis [38] numerous reports appeared describing the occurrence of EndoMT in 
various human pathologic conditions [37,42]. For example, Bertram and collaborators 
demonstrated that EndoMT played a significant role in the development of chronic kidney 
disease in diabetes observations that were expanded to include other causes of chronic renal 
failure [41]. In more recent studies, the possibility that EndoMT of portal vein endothelium via 
TGF-β/Smad activation may also be involved in portal venopathy was examined [48]. The 
results showed enhanced expression of phosphorylated Smad2 (pSmad2) in venous 
endothelium of smaller portal veins in idiopathic portal hypertension, which was associated with 
colocalization of EC and mesenchymal cell (myofibroblast) protein markers. The authors 
concluded that the conversion of portal vein EC into cells expressing a myofibroblastic 
phenotype may be responsible for exaggerated periportal-venous deposition of collagen and 
other fibrous tissue proteins, and may represent the ultimate mechanism responsible for portal 
venous obliteration in idiopathic portal hypertension. Other studies that described the 
occurrence of EndoMT in human disorders include the demonstration of EndoMT in the process 
of neointima formation in human vein graft tissues [47], the participation of EndoMT in the 
severe heterotopic ossification occurring in the course of fibrodysplasia ossificans progressiva 
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[49], and a prominent role in the development of intestinal fibrosis [45] and radiation induced 
rectal fibrosis [50]. 
4. EVIDENCE SUPPORTING THE ROLE OF ENDOMT IN SSC-ASSOCIATED ILD 
PULMONARY FIBROSIS AND PAH. 
4.1. Demonstration of EndoMT in primary or in SSc-associated PAH. Arciniegas et 
al. were among the first investigators to suggest a role of EndoMT in the pathogenesis of 
chronic PAH [116]. Following this novel suggestion, two more recent studies implicated EndoMT 
in the pathogenesis of PAH. The first study examined Primary PAH [117] and the second 
studied PAH secondary to SSc [112]. In the first study Ranchoux and co-workers  [117] applied 
transmission electron microscopy, and correlative light and electron microscopy, providing 
unequivocal ultrastructural-level evidence of ongoing dynamic EndoMT in lung tissue samples 
from patients with primary PAH. Indeed, they demonstrated that typical EC identified by the 
presence of Weibel-Palade bodies acquired expression of the myofibroblast-specific marker -
SMA, as well as, displayed invaginations into the neointima of the abnormal pulmonary 
arterioles. In the second study, Good et al. [112], assessed EndoMT in the pulmonary arterioles 
in lung tissues from patients with SSc-associated-PAH. Assessment of the cellular phenotype in 
intimal and plexiform lesions from PAH lungs showed the unambiguous expression of 
endothelial (CD31, CD34, VE-cadherin) and mesenchymal (-SMA) markers. A quantitative 
assessment of the co-expression of vWF and -SMA indicated that up to 4% of pulmonary 
arterioles in the lungs of patients with SSc-associated PAH displayed co-expression of EC and 
mesenchymal cell markers. Furthermore, the protein and mRNA expression patterns confirmed 
the notion of a key role of EndoMT in SSc-associated PAH pathology. The novel observations 
described in these two studies provide conclusive evidence for the occurrence of EndoMT in 
small and medium size arterioles of lung tissues from patients with both primary PAH and SSc-
associated PAH as discussed recently [118,119]. 
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4.2. Demonstration of EndoMT in lung tissues from patients with SSc-associated 
ILD. We recently performed a study to examine the possibility that Endo-MT is involved in the 
fibrotic process of SSc-associated ILD [120]. In this study lung tissues from six patients with 
SSc and pulmonary fibrosis and 2 normal lung controls were examined by histopathology, 
immunohistochemistry, and confocal laser microscopy for the simultaneous expression of 
markers of EC (CD31 and vWF) and myofibroblasts (α-SMA or type I collagen). 
Immunohistology studies showed expression of the EC marker CD31/PECAM in mesenchymal 
cells embedded within the neointima of small pulmonary arteries as well as in the parenchymal 
fibrotic areas in the six SSc lung specimens as illustrated in Figure 2. These observations 
demonstrated for the first time the presence of cells carrying EC molecular markers removed 
from the vessel endothelium and embedded within the fibrotic lung parenchyma in all SSc-
associated ILD samples examined. Co-expression of CD31 or vWF with the mesenchymal 
markers, collagen type I or α-SMA was demonstrated employing confocal laser microscopy in 
numerous EC lining the small and medium sized pulmonary arteries as illustrated for small 
arterioles in Figure 3. These findings were not present in the small or medium sized arteries of 
the normal lung tissues. The results demonstrated that EC co-expressing EC-specific and 
myofibroblastic cell markers are present in the endothelium of small pulmonary arteries from 
patients with SSc-associated pulmonary fibrosis and suggest that mesenchymal cells of 
endothelial origin are likely to be responsible for the production and accumulation of 
subendothelial fibrotic tissue in the affected vessels that in turn results in their luminal 
obliteration.  
These observations were confirmed by an extensive assessment of the differences in 
gene expression patterns between microvascular EC isolated from normal lungs compared to 
microvascular EC isolated from lungs from patients with SSc-ILD. The gene expression 
assessment of immunopurified CD31+/CD102+ EC obtained from lung tissues from two patients 
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with SSc-associated ILD compared to the average gene expression of immunopurified 
CD31+/CD102+ EC from two control lungs is shown in Figure 4. The results demonstrated a 
very strong expression of COL1A1 and COL3A1 in the CD31+/CD102+ purified EC from lungs 
from SSc patients and these values were up to 21 times and 26 times higher, respectively, than 
the expression of the same collagen genes in CD31+/CD102+ EC purified from the normal 
control lungs. The expression of FN1 and ACTA2 (-SMA), other profibrotic genes such as 
TGFB1 and CTGF, and that of several EndoMT-related genes such as SNAI2 and TWIST was 
also substantially increased in the CD31+/CD102+ EC from the lungs of SSc patients. Thus, we 
believe that the results of the extensive study performed in lung tissues from patients with SSc-
associated ILD provide conclusive evidence for the occurrence of EndoMT during the fibrotic 
process affecting the lungs in SSc.  
CONCLUDING REMARKS.  
The results of the various studies reviewed here including evidence from experimental 
animal models of tissue fibrosis and from several studies with tissues from patients with SSc-
associated ILD and PAH certainly indicate that the participation of EndoMT in these processes 
should no longer be considered a myth but it is, indeed, a reality. Furthermore, the results of 
these studies also suggest that greater understanding of the molecular mechanisms involved in 
EndoMT and its pharmacological modulation may represent a novel therapeutic approach for 
devastating effects and the high mortality of the SSc-associated tissue fibrosis and 
fibroproliferative vasculopathy complications that currently do not have effective therapies. 
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Figure Legends. 
Figure 1. Signaling pathways involved in SSc pathogenesis that may also play a role in 
EndoMT.  
The diagram shows the TGF-β, ET-1, NOTCH, and Wnt pathways, as well as, other putative 
pathways such as cellular stress and hypoxia that may participate in the EndoMT process and 
may be involved in SSc pathogenesis. One central pathway is initiated following TGF-β-binding 
and subsequent activation of the ALK-1-mediated Smad-independent TGF- pathway. 
Activation of this pathway causes phosphorylation of GSK-3 mediated by PKC-δ and the c-Abl 
non-receptor kinase. Phosphorylation of GSK-3 at serine 9 (ser9) causes its inhibition which 
then allows Snail-1 to enter the nucleus. Nuclear accumulation of Snail-1 results in marked 
stimulation of Snail-1 expression which then leads to acquisition of the myofibroblast phenotype 
with stimulation of -SMA expression. The inhibition of GSK-3 ser9 phosphorylation by specific 
inhibition of PKC-δ or c-Abl activity allows GSK-3β to phosphorylate Snail-1 targeting it for 
proteosomal degradation and thus, effectively abolishes the acquisition of the myofibroblastic 
phenotype and the fibrotic response. ET-1 effects appear to be mediated by a synergistic 
stimulation of TGF-β-induced EndoMT involving the canonical Smad pathways although the 
possibility of a direct stimulation of EndoMT by ET-1 has also been suggested. Other pathways 
such as those involving Wnt, NOTCH, hypoxia and cellular stress responses may also 
participate although the molecular events have not been fully elucidated. Modified from Ref. 
119. 
 
Figure 2. Histopathology and immunohistology of SSc-associated ILD lung tissues.  
A. A small artery in the lung of a patient with SSc-associated ILD shows severe narrowing of the 
vessel lumen with accumulation of elongated mesenchymal cells and large amounts of fibrous 
tissue in the subendothelial intimal space. B. Immunohistochemical staining of the same tissue 
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for the endothelial cell specific antibody marker CD31. Note the presence of CD31 positive cells 
in the subendothelial space besides their expected endothelial location. C. Lung tissue from 
another patient showing two cells bearing the EC-specific CD31 marker embedded within the 
neointimal tissue removed from the endothelium, and a CD31-positive cell cluster within the 
fibrotic lung parenchyma. D-F.  CD31 immunohistological staining of lung tissues from three 
additional SSc patients showing similar findings.  (Reproduced from Ref. 120 with permission).     
 
Figure 3. Confocal microscopy staining for vWF and α-SMA of a small arteriole in the 
lung of a patient with SSc-associated ILD.  
Staining for vWF is shown in green; staining for α-SMA is shown in red, and co-expression of 
vWF and α-SMA is shown in yellow in the merged image. All EC (vWF-stained) present within 
the endothelium and subendothelial tissue express the mesenchymal cell marker -SMA. 
(Reproduced from Ref. 120 with permission).     
 
Figure 4.  Quantitative PCR assessment and Western blot analysis of expression levels 
of selected genes and proteins in CD31+/CD102+ lung EC from SSc-associated ILD.   
Quantitative PCR of two different preparations of CD31+/CD102+ EC from lungs of two SSc 
patients or from normal lungs analyzed in duplicate. Shown are transcript measurements for 
interstitial collagen genes (COL1 and COL3), fibronectin 1 (FN1), α-SMA (SMA), EC-specific 
genes (COL4A1, VE-cadherin, vWF and VEGF), profibrotic genes (TGF-β1 and CTGF), and 
EndoMT-related transcription factors (SNAI2, and TWIST1). Fold change in CD31+/CD102+ EC 
from each of the SSc lungs (SSc1 and SSc2) compared to the average levels of the 
CD31+/CD102+ EC from the two normal lungs.  (Reproduced from Ref. 120 with permission).       
